Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to...

Key Takeaway: Alkermes plc will host a conference call on February 15, 2024, to discuss its fourth quarter and year-end financial results for 2023. The management will also outline financial expectations for 2024 and provide updates on the company's progress. Investors can access the call via phone or webcast.
Price reaction · baseline $26.7 (2024-02-07 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close · peak
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes will provide financial expectations for 2024.
  • The company is actively engaging with investors through a conference call.
  • Alkermes has a diverse portfolio of products targeting significant health issues.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Thursday, Feb. 15, 2024 to discuss the company's fourth quarter and year-end 2023 financial results. Management will also discuss financial expectations for 2024 and provide an update on the company.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland , Alkermes has a research and development center in Waltham , Massachusetts ; a research and manufacturing facility in Athlone , Ireland ; and a manufacturing facility in Wilmington, Ohio . For more information, please visit Alkermes ' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes report its financial results?

Alkermes will report its financial results on February 15, 2024.

How can I access the Alkermes conference call?

You can access the call by dialing +1 877 407 2988 for U.S. callers.

What will be discussed during the conference call?

The call will cover Q4 results, year-end results, and 2024 financial expectations.

Where is Alkermes headquartered?

Alkermes is headquartered in Dublin, Ireland.

Last updated: Feb 8, 2024